Education
About Us
Working with TipRanks
Follow Us
Zymeworks Inc (ZYME)
NASDAQ:ZYME
ZYME Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.03 - $18.35
Previous CloseN/A
Volume35.38K
Average Volume (3M)623.35K
Market Cap
$1.37B
Enterprise Value$708.40M
Total Cash (Recent Filing)$281.38M
Total Debt (Recent Filing)$18.68M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Nov 11, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.03
Shares Outstanding75,166,200
10 Day Avg. Volume721,160
30 Day Avg. Volume623,349
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.52
Enterprise Value/Revenue5.77
Enterprise Value/Gross Profit6.08
Enterprise Value/Ebitda-11.65
Forecast
1Y Price Target
$23.69Price Target Upside31.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentZanidatamab is likely to firmly establish itself as the standard-of-care across HER2+ mGEA, including in the PD-L1+ segment.
Financial OpportunitiesThere is a potential 30% stock upside for ZYME based on the updated scenario analyses.
Partnership BenefitsZYME is eligible to receive 10-20% tiered royalties, regulatory milestone payments of $525mn, and commercial milestone payments of $862.5mn from its partnership with JAZZ.
Bears Say
Clinical Development ChallengesZymeworks announced it has discontinued clinical development of ZW171, a 2+1 bispecific mesothelin-directed T cell engager.
Product DiscontinuationThe company will discontinue clinical development of ZW171 based on completion of the planned cohorts in the dose escalation portion of the Phase 1 trial.
Target ChallengesMesothelin was an interesting, but challenging target. CAR T targeting mesothelin has produced limited responses; TCE and antibody drug conjugate (ADC) approaches had fared no better.
Zymeworks News
ZYME FAQ
What was Zymeworks Inc’s price range in the past 12 months?
Zymeworks Inc lowest stock price was $9.03 and its highest was $18.35 in the past 12 months.
What is Zymeworks Inc’s market cap?
Zymeworks Inc’s market cap is $1.37B.
When is Zymeworks Inc’s upcoming earnings report date?
Zymeworks Inc’s upcoming earnings report date is Nov 11, 2025 which is in 28 days.
How were Zymeworks Inc’s earnings last quarter?
Zymeworks Inc released its earnings results on Aug 07, 2025. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.483 by $0.513.
Is Zymeworks Inc overvalued?
According to Wall Street analysts Zymeworks Inc’s price is currently Undervalued.
Does Zymeworks Inc pay dividends?
Zymeworks Inc does not currently pay dividends.
What is Zymeworks Inc’s EPS estimate?
Zymeworks Inc’s EPS estimate is -0.27.
How many shares outstanding does Zymeworks Inc have?
Zymeworks Inc has 75,166,200 shares outstanding.
What happened to Zymeworks Inc’s price movement after its last earnings report?
Zymeworks Inc reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.483. Following the earnings report the stock price went down -1.151%.
Which hedge fund is a major shareholder of Zymeworks Inc?
Currently, no hedge funds are holding shares in ZYME
Zymeworks Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$23.69 (31.17% Upside)
$23.69 (31.17% Upside)
Blogger Sentiment
Bullish
ZYME Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 733.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.5%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
40.65%
12-Months-Change
Fundamentals
Return on Equity
-19.89%
Trailing 12-Months
Asset Growth
-20.80%
Trailing 12-Months
Company Description
Zymeworks Inc
Zymeworks Inc. (NASDAQ: ZYME) is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer and other diseases. The company specializes in its proprietary therapeutic platforms, including Zymeworks' Azymetric and Zymeworks' ZymeLink, which enable the design and production of bispecific antibodies and other multi-specific therapeutics. Zymeworks is engaged in various stages of drug development and collaborates with pharmaceutical partners to advance its pipeline of candidates.
ZYME Company Deck
ZYME Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue growth, successful regulatory approvals, and promising advancements in the clinical and preclinical pipeline, supported by robust partnerships. However, there were concerns about reduced revenue in specific areas and ongoing cash burn. Additionally, questions about potential delays in the HERIZON-GEA-01 study results were raised.View all ZYME earnings summariesZYME Stock 12 Month Forecast
Average Price Target
$23.69
▲(31.17% Upside)
Technical Analysis
Arcus Biosciences
―
Replimune Group
―
Oric Pharmaceuticals
―
Nurix Therapeutics
―
Sana Biotechnology
―
Ownership Overview
33.14% Insiders
6.66% Mutual Funds
0.71% Other Institutional Investors
45.66% Public Companies and
Individual Investors